항응고제 시장(2026-2030년)

The global anticoagulants market is forecasted to grow by USD 22956.3 mn during 2025-2030, accelerating at a CAGR of 8.5% during the forecast period. The report on the global anticoagulants market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by accelerating prevalence of atrial fibrillation drives global prescription blood thinner consumption, clinical efficacy advantages accelerate phase out of legacy vitamin k antagonists, expanding pediatric and oncology indications broaden therapeutic application scope for anticoagulants.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.

Technavio's global anticoagulants market is segmented as below:

By Route Of Administration

• Oral anticoagulants
• Injectable anticoagulants

By Type

• Factor Xa inhibitors
• DTIs
• Heparin
• Vitamin K antagonists

By Distribution Channel

• Hospital pharmacy
• Retail pharmacy
• Online pharmacy

Geography

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
• Asia
• Rest of World (ROW)
• Rest of World (ROW)

This study identifies the emerging factor eleven inhibitors provide targeted antithrombotic protection without bleeding risks as one of the prime reasons driving the global anticoagulants market growth during the next few years. Also, development of targeted reversal agents enhances emergency hemostatic control and safety and long acting parenteral monoclonal antibodies transform patient compliance in chronic anticoagulation will lead to sizable demand in the market.

The report on the global anticoagulants market covers the following areas:

• Global anticoagulants market sizing
• Global anticoagulants market forecast
• Global anticoagulants market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading global anticoagulants market vendors that include Amneal Pharmaceuticals Inc., Aspen Pharmacare Ltd., AstraZeneca Plc, Aurobindo Pharma Ltd., Baxter International Inc., Bayer AG, Bristol Myers Squibb Co., Cipla Inc., Dr. Reddys Laboratories Ltd., Gland Pharma Ltd, Hikma Pharmaceuticals Plc, Johnson and Johnson, Organon and Co., Pfizer Inc., Sandoz Group AG, Sanofi SA, Sun Pharmaceutical Industries, Teva Pharmaceutical Ltd., Viatris Inc., Zydus Lifesciences Ltd.. Also, the global anticoagulants market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

Table of Contents

1 Executive Summary

• 1.1 Market overview
  • Executive Summary - Chart on Market Overview
  • Executive Summary - Data Table on Market Overview
  • Executive Summary - Chart on Global Market Characteristics
  • Executive Summary - Chart on Market by Geography
  • Executive Summary - Chart on Market Segmentation by Route of Administration
  • Executive Summary - Chart on Market Segmentation by Type
  • Executive Summary - Chart on Market Segmentation by Distribution Channel
  • Executive Summary - Chart on Incremental Growth
  • Executive Summary - Data Table on Incremental Growth
  • Executive Summary - Chart on Company Market Positioning

2 Technavio Analysis

• 2.1 Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
  • Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
• 2.2 Criticality of inputs and Factors of differentiation
• 2.3 Factors of disruption
• 2.4 Impact of drivers and challenges

3 Market Landscape

• 3.1 Market ecosystem
• 3.2 Market characteristics
• 3.3 Value chain analysis

4 Market Sizing

• 4.1 Market definition
• 4.2 Market segment analysis
  • Market segments
• 4.3 Market size 2025
• 4.4 Market outlook: Forecast for 2025-2030

5 Historic Market Size

• 5.1 Global Anticoagulants Market 2020 - 2024
  • Historic Market Size - Data Table on Global Anticoagulants Market 2020 - 2024 ($ million)
• 5.2 Route of Administration segment analysis 2020 - 2024
  • Historic Market Size - Route of Administration Segment 2020 - 2024 ($ million)
• 5.3 Type segment analysis 2020 - 2024
  • Historic Market Size - Type Segment 2020 - 2024 ($ million)
• 5.4 Distribution Channel segment analysis 2020 - 2024
  • Historic Market Size - Distribution Channel Segment 2020 - 2024 ($ million)
• 5.5 Geography segment analysis 2020 - 2024
  • Historic Market Size - Geography Segment 2020 - 2024 ($ million)
• 5.6 Country segment analysis 2020 - 2024
  • Historic Market Size - Country Segment 2020 - 2024 ($ million)

6 Qualitative Analysis

• 6.1 Impact of AI on global anticoagulants market
• 6.2 Impact of geopolitical conflicts on global anticoagulants market

7 Five Forces Analysis

• 7.1 Five forces summary
  • Five forces analysis - Comparison between 2025 and 2030
• 7.2 Bargaining power of buyers
  • Bargaining power of buyers - Impact of key factors 2025 and 2030
• 7.3 Bargaining power of suppliers
  • Bargaining power of suppliers - Impact of key factors in 2025 and 2030
• 7.4 Threat of new entrants
  • Threat of new entrants - Impact of key factors in 2025 and 2030
• 7.5 Threat of substitutes
  • Threat of substitutes - Impact of key factors in 2025 and 2030
• 7.6 Threat of rivalry
  • Threat of rivalry - Impact of key factors in 2025 and 2030
• 7.7 Market condition

8 Market Segmentation by Route of Administration

• 8.1 Market segments
• 8.2 Comparison by Route of Administration
• 8.3 Oral anticoagulants - Market size and forecast 2025-2030
• 8.4 Injectable anticoagulants - Market size and forecast 2025-2030
• 8.5 Market opportunity by Route of Administration
  • Market opportunity by Route of Administration ($ million)

9 Market Segmentation by Type

• 9.1 Market segments
• 9.2 Comparison by Type
• 9.3 Factor Xa inhibitors - Market size and forecast 2025-2030
• 9.4 DTIs - Market size and forecast 2025-2030
• 9.5 Heparin - Market size and forecast 2025-2030
• 9.6 Vitamin K antagonists - Market size and forecast 2025-2030
• 9.7 Market opportunity by Type
  • Market opportunity by Type ($ million)

10 Market Segmentation by Distribution Channel

• 10.1 Market segments
• 10.2 Comparison by Distribution Channel
• 10.3 Hospital pharmacy - Market size and forecast 2025-2030
• 10.4 Retail pharmacy - Market size and forecast 2025-2030
• 10.5 Online pharmacy - Market size and forecast 2025-2030
• 10.6 Market opportunity by Distribution Channel
  • Market opportunity by Distribution Channel ($ million)

11 Customer Landscape

• 11.1 Customer landscape overview
  • Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

12 Geographic Landscape

• 12.1 Geographic segmentation
• 12.2 Geographic comparison
• 12.3 North America - Market size and forecast 2025-2030
  • 12.3.1 US - Market size and forecast 2025-2030
  • 12.3.2 Canada - Market size and forecast 2025-2030
  • 12.3.3 Mexico - Market size and forecast 2025-2030
• 12.4 Europe - Market size and forecast 2025-2030
  • 12.4.1 Germany - Market size and forecast 2025-2030
  • 12.4.2 UK - Market size and forecast 2025-2030
  • 12.4.3 France - Market size and forecast 2025-2030
  • 12.4.4 Italy - Market size and forecast 2025-2030
  • 12.4.5 Spain - Market size and forecast 2025-2030
  • 12.4.6 The Netherlands - Market size and forecast 2025-2030
• 12.5 Asia - Market size and forecast 2025-2030
  • 12.5.1 China - Market size and forecast 2025-2030
  • 12.5.2 Japan - Market size and forecast 2025-2030
  • 12.5.3 India - Market size and forecast 2025-2030
  • 12.5.4 South Korea - Market size and forecast 2025-2030
  • 12.5.5 Singapore - Market size and forecast 2025-2030
  • 12.5.6 Thailand - Market size and forecast 2025-2030
• 12.6 Rest of World (ROW) - Market size and forecast 2025-2030
  • 12.6.1 Brazil - Market size and forecast 2025-2030
  • 12.6.2 Saudi Arabia - Market size and forecast 2025-2030
  • 12.6.3 UAE - Market size and forecast 2025-2030
  • 12.6.4 South Africa - Market size and forecast 2025-2030
  • 12.6.5 Argentina - Market size and forecast 2025-2030
  • 12.6.6 Egypt - Market size and forecast 2025-2030
  • 12.6.7 Chile - Market size and forecast 2025-2030
  • 12.6.8 Israel - Market size and forecast 2025-2030
• 12.7 Market opportunity by geography
  • Market opportunity by geography ($ million)
  • Data Tables on Market opportunity by geography ($ million)

13 Drivers, Challenges, and Opportunity

• 13.1 Market drivers
  • Accelerating prevalence of atrial fibrillation drives global prescription blood thinner consumption
  • Clinical efficacy advantages accelerate phase out of legacy vitamin k antagonists
  • Expanding pediatric and oncology indications broaden therapeutic application scope for anticoagulants
• 13.2 Market challenges
  • Major bleeding risks associated with direct oral anticoagulants impair prescribing confidence
  • Patent exclusivity extensions for branded oral anticoagulants delay generic market availability
  • Prohibitive drug acquisition costs restrict patient access across low income healthcare networks
• 13.3 Impact of drivers and challenges
  • Impact of drivers and challenges in 2025 and 2030
• 13.4 Market opportunities
  • Emerging factor eleven inhibitors provide targeted antithrombotic protection without bleeding risks
  • Development of targeted reversal agents enhances emergency hemostatic control and safety
  • Long acting parenteral monoclonal antibodies transform patient compliance in chronic anticoagulation

14 Competitive Landscape

• 14.1 Overview
• 14.2 Competitive Landscape
  • Overview on criticality of inputs and factors of differentiation
• 14.3 Landscape disruption
  • Overview on factors of disruption
• 14.4 Industry risks
  • Impact of key risks on business

15 Competitive Analysis

• 15.1 Companies profiled
  • Companies covered
• 15.2 Company ranking index
  • Company ranking index
• 15.3 Market positioning of companies
  • Matrix on companies position and classification
• 15.4 AstraZeneca Plc
  • AstraZeneca Plc - Overview
  • AstraZeneca Plc - Business segments
  • AstraZeneca Plc - Key news
  • AstraZeneca Plc - Key offerings
  • AstraZeneca Plc - Segment focus
  • SWOT
• 15.5 Baxter International Inc.
  • Baxter International Inc. - Overview
  • Baxter International Inc. - Business segments
  • Baxter International Inc. - Key news
  • Baxter International Inc. - Key offerings
  • Baxter International Inc. - Segment focus
  • SWOT
• 15.6 Bayer AG
  • Bayer AG - Overview
  • Bayer AG - Business segments
  • Bayer AG - Key news
  • Bayer AG - Key offerings
  • Bayer AG - Segment focus
  • SWOT
• 15.7 Bristol Myers Squibb Co.
  • Bristol Myers Squibb Co. - Overview
  • Bristol Myers Squibb Co. - Product / Service
  • Bristol Myers Squibb Co. - Key news
  • Bristol Myers Squibb Co. - Key offerings
  • SWOT
• 15.8 Cipla Inc.
  • Cipla Inc. - Overview
  • Cipla Inc. - Business segments
  • Cipla Inc. - Key news
  • Cipla Inc. - Key offerings
  • Cipla Inc. - Segment focus
  • SWOT
• 15.9 Dr. Reddys Laboratories Ltd.
  • Dr. Reddys Laboratories Ltd. - Overview
  • Dr. Reddys Laboratories Ltd. - Business segments
  • Dr. Reddys Laboratories Ltd. - Key news
  • Dr. Reddys Laboratories Ltd. - Key offerings
  • Dr. Reddys Laboratories Ltd. - Segment focus
  • SWOT
• 15.10 Gland Pharma Ltd
  • Gland Pharma Ltd - Overview
  • Gland Pharma Ltd - Product / Service
  • Gland Pharma Ltd - Key offerings
  • SWOT
• 15.11 Johnson and Johnson
  • Johnson and Johnson - Overview
  • Johnson and Johnson - Business segments
  • Johnson and Johnson - Key news
  • Johnson and Johnson - Key offerings
  • Johnson and Johnson - Segment focus
  • SWOT
• 15.12 Pfizer Inc.
  • Pfizer Inc. - Overview
  • Pfizer Inc. - Business segments
  • Pfizer Inc. - Key news
  • Pfizer Inc. - Key offerings
  • Pfizer Inc. - Segment focus
  • SWOT
• 15.13 Sandoz Group AG
  • Sandoz Group AG - Overview
  • Sandoz Group AG - Business segments
  • Sandoz Group AG - Key news
  • Sandoz Group AG - Key offerings
  • Sandoz Group AG - Segment focus
  • SWOT
• 15.14 Sanofi SA
  • Sanofi SA - Overview
  • Sanofi SA - Business segments
  • Sanofi SA - Key news
  • Sanofi SA - Key offerings
  • Sanofi SA - Segment focus
  • SWOT
• 15.15 Sun Pharmaceutical Industries
  • Sun Pharmaceutical Industries - Overview
  • Sun Pharmaceutical Industries - Business segments
  • Sun Pharmaceutical Industries - Key news
  • Sun Pharmaceutical Industries - Key offerings
  • Sun Pharmaceutical Industries - Segment focus
  • SWOT
• 15.16 Teva Pharmaceutical Ltd.
  • Teva Pharmaceutical Ltd. - Overview
  • Teva Pharmaceutical Ltd. - Business segments
  • Teva Pharmaceutical Ltd. - Key news
  • Teva Pharmaceutical Ltd. - Key offerings
  • Teva Pharmaceutical Ltd. - Segment focus
  • SWOT
• 15.17 Viatris Inc.
  • Viatris Inc. - Overview
  • Viatris Inc. - Business segments
  • Viatris Inc. - Key news
  • Viatris Inc. - Key offerings
  • Viatris Inc. - Segment focus
  • SWOT
• 15.18 Zydus Lifesciences Ltd.
  • Zydus Lifesciences Ltd. - Overview
  • Zydus Lifesciences Ltd. - Business segments
  • Zydus Lifesciences Ltd. - Key news
  • Zydus Lifesciences Ltd. - Key offerings
  • Zydus Lifesciences Ltd. - Segment focus
  • SWOT

16 Appendix

• 16.1 Scope of the report
  • Market definition
  • Objectives
  • Notes and caveats
• 16.2 Inclusions and exclusions checklist
  • Inclusions checklist
  • Exclusions checklist
• 16.3 Currency conversion rates for US$
  • Currency conversion rates for US$
• 16.4 Research methodology
  • Research methodology
• 16.5 Data procurement
  • Information sources
• 16.6 Data validation
  • Data validation
• 16.7 Validation techniques employed for market sizing
  • Validation techniques employed for market sizing
• 16.8 Data synthesis
  • Data synthesis
• 16.9 360 degree market analysis
  • 360 degree market analysis
• 16.10 List of abbreviations
  • List of abbreviations